Industry News
Excerpt from the Press Release: SARASOTA, Fla. and NOVATO, Calif., May 19, 2021 (GLOBE NEWSWIRE) — GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced that they have received clearance from Health Canada to begin enrolling the Phase…
Read More
Excerpt from the Press Release: BURLINGTON, Mass. & OXFORD, England–(BUSINESS WIRE)–Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, is pleased to share news of the publication of a study from researchers at Winship Cancer Institute of Emory University (Winship) evaluating Axumin® (fluciclovine F 18) PET…
Read More
Excerpt from the Press Release: Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces positive topline results from the head-to-head phase 3 OCEAN study evaluating the efficacy and safety of melphalan flufenamide versus pomalidomide in patients with relapsed refractory multiple myeloma (RRMM).…
Read More
Excerpt from the Press Release: SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) — AXIM®Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has completed pre-clinical drug studies on its patent pending compound SPX-1009, demonstrating the suppression of malignant metastatic melanoma cells. The…
Read More
Excerpt from the Article: The U.S. Food and Drug Administration gave an emergency use authorization to the antibody treatment developed by Vir Biotechnology and GlaxoSmithKline for treating mild-to-moderate Covid-19 in people aged 12 years and older. The antibody drug, Sotrovimab, is not authorized for patients who are hospitalized due to Covid-19 or require oxygen therapy, the health regulator said…
Read More
Excerpt from the Press Release: When COVID-19 shut down the world’s economies, governments across the globe, including the United States, began to pour money into vaccine research and development. Those funds led to the rapid development and deployment of vaccines, but few therapeutics against the virus have achieved the same speed of development. And that may…
Read More
On May 25th, 2021 TrialStat’s very own Christopher Kata, and Heather Williams hosted an incredible webinar with our guest Speaker John Amrhein, VP of McDougall Scientific. John presented his perspective on “Accelerating Trials Through Innovative Clinical Trial Designs” and taking questions from our live audience! Download the Slide Deck, and Watch The Webinar Recording On…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Freenome, the privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection using a routine blood draw, today announced results from two different studies using “CRC – Microsimulation of Adenoma Progression and Screening”, or CRC-MAPS™, a novel semi-Markov microsimulation model of…
Read More Meet with Christopher Kata, Director of Sales & Marketing on June 27 – July 1st! Christopher Kata, Director of Sales & Marketing905 [email protected] When: June 27th – July 1st 2021Where: It’s Virtual!Registration: https://www.diaglobal.org/en/cart Recognizing and adapting to a new era of global change and uncertainty, DIA’s key tenets remain unchanged. Patients are our story, we…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass. & FARGO, N.D.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, LLC, the leading provider of high-quality plasmid DNA, mRNA and recombinant proteins necessary for vaccines, gene and cell therapy, gene editing and diagnostic applications, have announced their expanded collaboration in…
Read More